A coronavirus vaccine being developed at the University of Oxford is showing promise in human trials.
The BBC is reporting trials involving 1,077 people saw the injection lead to them creating antibodies and T-cells that fight COVID-19.
While the findings are promising, it is still too soon to know if the vaccine will provide enough protection. Larger trials are underway.
The vaccine, called ChAdOx1 nCoV-19, is being made from a genetically engineered virus that causes the common cold in chimpanzees.
The vaccine trial saw levels of T-cells peak 14 days after vaccination and antibody levels peak after 28 days.
The study was not run long enough to know how long they would last.
Ninety per cent of study participants developed sufficient antibodies after just one dose.
Seventy per cent of those taking the vaccine developed fever or headache, something researchers believe could be managed with paracetamol.
